Inclisiran in advanced chronic kidney disease (stage G4-G5 non-dialysis): sustained LDL-C reduction and favorable safety profile at 1-year follow-up in a real-world case series.

Leqvio (inclisiran) - Novartis

http://www.ncbi.nlm.nih.gov/pubmed/42440710

Adriana Puente García; Arturo Villalobos Navarro; Avinash Chandu Nanwani; Celia Rodríguez Tudero; Elena Jiménez Mayor; Esperanza Moral Berrio; Jesús Hernández Vaquero; José Carlos De La Flor Merino; Juan Daniel Diaz Garcia

Jul 14, 2026